Offering $200 Off the First CoolSculpting® Treatment IRVINE, Calif., April 3, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) is announcing its second annual CoolMonth celebration featuring CoolSculpting® Elite. From April 1 through April 30, 2024, consumers can access CoolSavings promotions to help accelerate their body contouring journey. Leveraging last year's success, which saw more than 62,000 treatments during the month-long celebration1, the brand aims to encourage and inspi ...

The big money might be feeling a bit queasy about overexposure to risk-on assets, presenting a framework to follow regarding the best stocks to buy in April.As I’ve mentioned many times before, technology-related securities saw an outflow recently of $4.4 billion. That was the largest ever outflow over a one-week period. Effectively, the dynamic communicates that the smart money want to diversify their exposure.If so, retail investors should also consider pivoting some of their weighting based on these shif ...

The most recent trading session ended with AbbVie (ABBV) standing at $180.76, reflecting a -0.74% shift from the previouse trading day's closing. This move lagged the S&P 500's daily loss of 0.2%. At the same time, the Dow lost 0.6%, and the tech-heavy Nasdaq gained 0.11%.The drugmaker's shares have seen an increase of 1.78% over the last month, not keeping up with the Medical sector's gain of 2.21% and the S&P 500's gain of 3.32%.Analysts and investors alike will be keeping a close eye on the performance o ...

gustavofrazao In this series, I rank a selection of Dividend Radar stocks and present the ten top-ranked stocks for further research and possible investment. Dividend Radar is a weekly automatically generated spreadsheet of dividend growth [DG] stocks with dividend increase streaks of five or more years. In February, I presented candidates with high earnings, revenue, and dividend growth rates trading at favorable valuations. Additionally, I screened for stocks with 5-year trailing total returns above ...

There are many ways the stock market can help you get rich, but not every method is right for you. If you're someone who enjoys keeping tabs on fast-moving industries, chasing popular growth stocks makes sense. For those of us who are more concerned with retiring comfortably, finding stocks we can rely on for steady gains over long periods is a much better strategy.If there's one corner of the economy that you can rely on for steady growth, it's the healthcare sector. U.S. healthcare expenses grew 4.1% to $ ...

Andrii Borodai/iStock via Getty Images Alderya – Overview Aldeyra (NASDAQ:ALDX or the Company), is a small cap, development-stage biotech company with a portfolio of RASP (reactive aldehyde species) modulating compounds. The lead drug is a topical therapy for dry eye disease, reproxalap, that recently received a complete response letter (CRL), a rejection from the FDA. The Company believes it has a clear path to provide additional data and obtain approval for reproxalap in early 2025. The Company also h ...

ToplineThe Food and Drug Administration said Friday it granted full approval to AbbVie and ImmunoGen’s cancer drug mirvetuximab-soravtansine-gynx, or Elahere, part of a new class of cancer treatments considered “biological missiles” because of their ability to precisely home in on cancer cells.FILE - A sign for the U.S. Food and Drug Administration is displayed outside their offices in Silver ... [+] Spring, Md., Dec. 10, 2020. (AP Photo/Manuel Balce Ceneta, File)Copyright 2020 The Associated Press. All rig ...

-       The full approval of ELAHERE is based on the confirmatory MIRASOL Phase 3 trial that supports the medicine as a potential new standard of care for folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer (PROC) -       Data show that ELAHERE treatment resulted in an overall survival benefit and reduced the risk of cancer progression by 35% -       ELAHERE represents AbbVie's first approved solid tumor treatment following the recent acquisition of ImmunoGen NORTH CHICAGO, Ill., March 2 ...

Finding high-yielding companies isn't everything when investing in dividend stocks. Sometimes, companies' yields increase after their share prices drop significantly, which can occasionally be a sign that the business could be in trouble and may have to decrease its payouts. So before investing in a high-yield dividend stock, it's essential to ensure that its underlying business is solid and will likely continue to hike its dividends.Let's look at two companies with yields higher than the S&P 500 average th ...

AbbVie Inc. (NYSE:ABBV) Barclays 26th Annual Global Healthcare Conference Call March 14, 2024 9:00 AM ET Company Participants Rob Michael - President & Chief Executive Officer Scott Reents - Executive Vice President & Chief Financer Roopal Thakkar - Senior Vice President of Development & Regulatory Affairs and Chief Medical Officer Jeff Stewart - Executive Vice President & Chief Commercial Officer Conference Call Participants Carter Gould - Barclays Carter Gould Good morning and welcome to Day 3 of the Barc ...